VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors
16 January 2019 - 12:30AM
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage
biopharmaceutical company developing new generation medicines for
central nervous system (CNS) diseases and disorders with high unmet
need, today announced the appointment of pharmaceutical industry
veteran, Ann Cunningham, to the Company’s Board of Directors and
its Corporate Governance and Nominating Committee.
“We are delighted to welcome Ann to our Board of Directors,”
stated Shawn Singh, Chief Executive Officer of VistaGen. “With
decades of commercial and leadership experience in the
pharmaceutical industry, experience that is especially relevant in
the depression and other CNS markets we are pursuing, Ann’s
expertise expands our Board’s strengths. We look forward to
her valuable insights and strategic guidance as we continue to
advance our pipeline programs.”
Ms. Cunningham currently serves as Managing Partner of i3
Strategy Partners where she guides pharmaceutical and biotechnology
executives in planning and executing successful portfolio
strategies and brand launches by evaluating key business questions
and evaluating unique strategies to unlock the full potential of
each organization served. Her experience in the pharmaceutical
industry includes time served in multiple instrumental roles,
including: Vice President, Neurodegenerative Disease and Psychiatry
at Teva Pharmaceutical Industries; Senior Director, Global Brand
Lead, Rexulti, at Otsuka America Pharmaceutical; and Senior
Director, Global Brand Lead and Sales Director in multiple
therapeutic areas at Eli Lilly and Company, including Psychiatry.
Ms. Cunningham holds a B.A. in Psychology from Yale University and
an M.B.A. from University of Michigan, Stephen M. Ross School of
Business.
“With three late-stage, fast-acting new generation CNS drug
candidates, each focused on a large market where millions of
individuals need new safe and effective alternatives to current
therapies, VistaGen is poised to make game-changing advances in the
near future,” said Ms. Cunningham. “I am eager to begin working
with VistaGen’s leadership team at this exciting and potentially
transformative time in the Company’s development.”
About VistaGen VistaGen Therapeutics is a
clinical-stage biopharmaceutical company developing new generation
medicines for multiple CNS diseases and disorders with high unmet
need. Each of VistaGen’s CNS pipeline candidates, AV-101, PH10 and
PH94B, has fast-acting activity and potential to be safer and
better tolerated than current drugs in its target markets. The
Company is currently focused on five CNS markets: major depressive
disorder (MDD); neuropathic pain (NP); Parkinson’s disease
levodopa-induced dyskinesia (PDLID); social anxiety disorder (SAD);
and suicidal ideation. Each drug candidate in VistaGen’s CNS
pipeline is either currently in, or has completed, Phase 2 POC
clinical development. AV-101, an oral NMDA receptor glycine B
antagonist, is in Phase 2 clinical development as an adjunctive
treatment of MDD and is being prepared for initial Phase 2 clinical
studies in NP and PDLID. The FDA has granted Fast Track
designation for development of AV-101 as both a potential
adjunctive treatment of MDD and as a non-opioid treatment for
neuropathic pain. PH10 intranasal, a first-in-class neuroactive
steroid with rapid onset effects, has completed a successful Phase
2 POC clinical study for MDD. PH94B intranasal, also a
first-in-class neuroactive steroid with rapid onset effects, has
completed Phase 2 clinical development and is now being prepared
for pivotal Phase 3 clinical development as an on-demand, as needed
(PRN) treatment of SAD.
For more information, please
visit www.vistagen.com and connect with VistaGen on
Twitter, LinkedIn and Facebook.
Forward-Looking StatementsThis release contains
various statements concerning VistaGen's future expectations, plans
and prospects, including without limitation, our expectations
regarding development and commercialization of our drug candidates,
all of which constitute forward-looking statements for the purposes
of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
neither promises nor guarantees of future performance and are
subject to a variety of risks and uncertainties, many of which are
beyond our control, and may cause actual results to differ
materially from those contemplated in these forward-looking
statements. Among these risks is the possibility that (i) we may
encounter unexpected adverse events in patients during our clinical
development of any product candidate that cause us to discontinue
further development, (ii) we may not be able to successfully
demonstrate the safety and efficacy of our product candidates at
each stage of clinical development, (iii) success in preclinical
studies or in early-stage clinical trials may not be repeated or
observed in ongoing or future studies, and ongoing or future
preclinical and clinical results may not support further
development of, or be sufficient to gain regulatory approval to
market AV-101, PH94B, and/or PH10, (iv) decisions or actions of
regulatory agencies may negatively affect the progress of, and our
ability to proceed with, further clinical studies or to obtain
marketing approval for our drug candidates, (v) we may not be able
to obtain or maintain adequate intellectual property protection and
other forms of marketing and data exclusivity for our product
candidates, (vi) we may not have access to or be able to secure
substantial additional capital to support our operations, including
our ongoing clinical development activities, and (vii) we may
encounter technical and other unexpected hurdles in the
manufacturing and development of any of our product candidates.
Certain other risks are more fully discussed in the section
entitled "Risk Factors" in our most recent annual report on Form
10-K, and subsequent quarterly reports on Form 10-Q, as well as
discussions of potential risks, uncertainties, and other important
factors in our other filings with the Securities and Exchange
Commission (SEC). Our SEC filings are available on the SEC's
website at www.sec.gov. In addition, any forward-looking
statements represent our views only as of the issuance of this
release and should not be relied upon as representing our views as
of any subsequent date. We explicitly disclaim any obligation to
update any forward-looking statements.
Company Contact Mark A. McPartland VistaGen
Therapeutics Inc. Phone: +1 (650) 577-3600
Email: IR@vistagen.com
Investor Contact Valter Pinto / Allison Soss
KCSA Strategic Communications Phone: +1 (212) 896-1254/+1 (212)
896-1267 Email: VistaGen@KCSA.com
Media Contact Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications Phone: +1 (212) 896-1241/+1 (508)
843-6428 Email: VistaGen@KCSA.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to May 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From May 2023 to May 2024